Respiratory Inhalers Market is Expected to Escalate at a CAGR of 5.38% and Reach USD 47.83 Billion by 2026, Analyzes DelveInsight

The Respiratory Inhalers market is anticipated to surge due to various factors such as the escalating burden of various respiratory disorders such as asthma attacks, COPD, among others, and the growing adoption of digital technologies by the leading pharmaceutical giants to provide better solutions for the management of respiratory disorders are some of the factors expected to impel the global Respiratory Inhalers market in the forthcoming years.

LAS VEGAS, March 17, 2022 /PRNewswire/ -- DelveInsight's Respiratory Inhalers Market Insights and Forecast report provides the current and forecast Respiratory Inhalers Market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Respiratory Inhalers Market.

DelveInsight Logo
DelveInsight Logo

Some of the salient features from the Respiratory Inhalers Market report:

  • As per DelveInsight analysis, in terms of revenue share, North America is predicted to register the fastest growth in the Respiratory Inhalers market.

  • Major Respiratory Inhalers market players proactively working in the field include names like Novartis AG, AstraZeneca, GlaxoSmithKline plc, CHIESI Farmaceutici S.p.A., Lupin, Zydus Cadila, Teva Pharmaceutical Industries Ltd., OMRON, Koninklijke Philips N.V., PARI GmbH, Boehringer Ingelheim International GmbH., Glenmark Pharmaceuticals Limited, Lepu Medical Technology(Beijing)Co., Ltd., Rossmax International Ltd, Promed Technology Co., Limited, HELTMAN Medikal A.S., Pneuma Respiratory., Cipla Inc., Microlife Corporation., Honsun, and others.

  • DelveInsight analyzes that the Global Respiratory Inhalers market is expected to reach USD 47.83 billion by 2026 growing at a CAGR of 5.38% during the forecast period from 2021 to 2026.

  • In September 2020, GlaxoSmithKline plc and Innoviva, Inc. received FDA approval for Trelegy Ellipta as the first once-daily single inhaler triple therapy for the treatment of both Asthma and COPD in the US.

  • In July 2020, Novartis received the European Commission (EC) approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside treatment for uncontrolled asthma in the EU.

  • In January 2020, Aptar Pharma partnered with Lupin to launch India's first connected smart device for respiratory disease, ADHERO.

  • in May 2020, Propeller Health, one of the leading digital health companies dedicated to the management of asthma and COPD received FDA clearance to bring its connected platform to AstraZeneca's Symbicort to help digitize the treatment of asthma and chronic obstructive pulmonary disease (COPD).

  • in May 2020, Iconovo received CE mark approval for its capsule-based dry powder inhaler ICOcap™ for use in clinical trials.

  • In July 2020, Teva Respiratory, LLC., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. launched ProAir® Digihaler® (albuterol sulfate 117 mcg) Inhalation Powder for Patients with Asthma and COPD.

To pick on the latest highlights related to Respiratory Inhalers, get the snapshot of the key highlights entailed in the Respiratory Inhalers Market Report

Respiratory Inhalers Overview

Respiratory Inhalers are portable devices used to deliver medications for obstructive airway diseases such as Chronic Obstructive Pulmonology Disorders (COPD), asthma, among others into the airways. Inhaled pharmacologic therapies are the cornerstone of treatment and prevention for patients suffering from asthma and COPD. The inhalers provide the benefit of avoiding the systemic exposure of drugs and are delivered topically into the airways leading to local efficacy within the lungs in comparison to oral or parenteral formulations. Generally, respiratory inhalers are of four types: pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs), slow mist inhalers (SMIs), and nebulizers.

Respiratory Inhalers Market Insight

Among all the regions, North America is expected to occupy a major share in the overall Respiratory Inhalers market during the forthcoming years. This domination is owing to the increasing prevalence of COPD in the region. Additionally, increase in adoption of technologically advanced Respiratory Inhalers, growing product launches associated with inhalers in the region, presence of well-established healthcare facilities, and rising government initiatives to raise awareness regarding respiratory disorders and their proper management in the region, as well as the presence of key Respiratory Inhalers companies are expected to escalate the Respiratory Inhalers market.

For instance, On December 07, 2020, AireHealth, an innovative digital health company received 510(k) FDA clearance for its connected nebulizer.

Click here to Understand more about the Respiratory Inhalers Market Landscape @ Respiratory Inhalers Market Assessment

Respiratory Inhalers Market Dynamics

The Global Respiratory Inhalers market is projected to witness significant growth owing to the rising approval and launches of various technological products in the Respiratory Inhalers market. In addition, degrading air quality and rise in air pollution, growing awareness regarding inhalers and their use to control respiratory disorders, and an increase in smoking among the population across the globe would contribute to the rise in the Respiratory Inhalers market. In addition, rising efforts by key players to raise awareness regarding the use of inhalers in controlling various obstructive airway diseases are also expected to rise the adoption of Respiratory Inhalers among the patient population thereby bolstering the Respiratory Inhalers market during the forecasted period. Moreover, decreasing air quality in industrialized areas due to increasing air pollution is also a key factor propelling the Respiratory Inhalers market.

The COVID-19 pandemic had a limited effect on the Respiratory Inhalers market. During the initial phase of the pandemic due to the implementation of stringent nationwide lockdown, various healthcare facilities were disrupted. However, it is estimated that people severely affected with COVID-19 infection may develop respiratory illness as an after effect which will surge the demand for Respiratory Inhalers among the COVID recovering patients. Also, various clinical trials are ongoing at present to study the efficacy of asthma inhalers on COVID-19 patients. Furthermore, the launch of vaccines and their administration across the globe will normalize the Respiratory Inhalers market situation in the post-pandemic situation.

To gain a better understanding of the COVID-19 impact on Respiratory Inhalers, get a snapshot of the Respiratory Inhalers Market Analysis

Scope of the Respiratory Inhalers Market Report

  • Coverage: Global

  • Study Period: 2021-2026

  • Market Segmentation By Product Type - Dry Powder Inhaler, Metred Dose Inhaler, Soft Mist Inhalers, Nebulizers [Ultrasonic Nebulizers, Mesh Nebulizers, And Compressor Nebulizers

  • Market Segmentation By Type - Conventional Inhaler Devices And Smart Inhaler Devices

  • Market Segmentation By Patient Type- Adult And Pediatrics

  • Market Segmentation By Indication- Asthma, COPD, And Others

  • Market Segmentation By Geography - North America, Europe, Asia-Pacific, and Rest of World

  • Key Respiratory Inhalers Companies - Novartis AG, AstraZeneca, GlaxoSmithKline plc, CHIESI Farmaceutici S.p.A., Lupin, Zydus Cadila, Teva Pharmaceutical Industries Ltd., OMRON, Koninklijke Philips N.V., PARI GmbH, Boehringer Ingelheim International GmbH., Glenmark Pharmaceuticals Limited, Lepu Medical Technology(Beijing)Co., Ltd., Rossmax International Ltd, Promed Technology Co., Limited, HELTMAN Medikal A.S., Pneuma Respiratory., Cipla Inc., Microlife Corporation., Honsun, and others.

  • Porter's Five Forces Analysis

  • Product Profiles

  • Case Studies

  • KOL's Views

  • Analyst's View

Delveinsight Analysis: The Global Respiratory Inhalers market is expected to reach USD 47.83 billion by 2026 growing at a (Compound Annual Growth Rate) CAGR of 5.38% during the forecast period from 2021 to 2026.

Know more about which MedTech player is set to emerge as the trendsetter @ Respiratory Inhalers Market Landscape Analysis

Table of Contents

1

Respiratory Inhalers Market Report Introduction

2

Respiratory Inhalers Market Executive summary

3

Regulatory and Patent Analysis

4

Respiratory Inhalers Market Key Factors Analysis

5

Respiratory Inhalers Market Porter's Five Forces Analysis

6

COVID-19 Impact Analysis on Respiratory Inhalers Market

7

Respiratory Inhalers Market Layout

8

Respiratory Inhalers Market Global Company Share Analysis – Key 3-5 Companies

9

Respiratory Inhalers Market Company and Product Profiles


9.1 Novartis AG

9.2 AstraZeneca

9.3 GlaxoSmithKline plc

9.4 CHIESI Farmaceutici S.p.A.

9.5 Lupin

9.6 Zydus Cadila

9.7 Teva Pharmaceutical Industries Ltd.

9.8 OMRON

9.9 Koninklijke Philips N.V.

9.10 PARI GmbH

10

Project Approach

11

KOL Views

12

DelveInsight Capabilities

13

Disclaimer

14

About DelveInsight

Learn more about the report offerings @ Respiratory Inhalers Market Outlook

Pulse Oximeters Market

DelveInsight's 'Pulse Oximeters Market Insights, Competitive Landscape and Market Forecast - 2026' report deliver an in-depth understanding of Pulse Oximeters, historical and forecasted Pulse Oximeters market trends, market drivers, market barriers, and key companies involved like Medtronic, Nonin Medical Inc, Lepu Medical Technology, TytoCare Ltd, VYAIRE, OMRON Corporation. Meditech Equipment Co ., Ltd, and several others.

Cough Assist Devices Market

"DelveInsight's 'Cough Assist Devices Market Insight, Competitive Landscape and Market Forecast, 2026' report delivers an in-depth understanding of Cough Assist Devices and the historical and forecasted Cough Assist Devices market trends, market drivers & barriers, unmet needs and key companies involved such as Koninklijke Philips N.V, Percussionaire Corp., Emerson, Hill Rom, Dima Italia SRL, and many more.

Cough in Idiopathic Pulmonary Fibrosis Market

DelveInsight's 'Cough in Idiopathic Pulmonary Fibrosis (IPF)-Market Insights, Epidemiology and Market Forecast– 2030' report delivers an in-depth understanding of the cough in IPF, historical and forecasted epidemiology as well as the Cough in IPF market trends, market drivers & barriers, unmet needs and key companies involved such as Algernon Pharmaceuticals, Trevi Therapeutics, Nerre Therapeutics, and others.

Chronic Obstructive Pulmonary Disease Market

DelveInsight's 'Chronic Obstructive Pulmonary Disease (COPD)-Market Insights, Epidemiology, and Market Forecast–2030' report deliver an in-depth understanding of the Chronic Obstructive Pulmonary Disease (COPD), historical and forecasted epidemiology as well as the Chronic Obstructive Pulmonary Disease (COPD) market trends, market drivers & barriers, unmet needs and key companies involved such as AstraZeneca, Amgen, Circassia Pharmaceuticals Inc, Biomarck Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Chiesi Farmaceutici, Genentech, GlaxoSmithKline, Theravance, Innoviva, Inmunotek, Mereo BioPharma, Novartis Pharmaceuticals, and several others.

Airway Management Devices Market

Global Airway Management Devices Market was valued at USD 1.51 billion in 2020, growing at a CAGR of 6.20% during the forecast period from 2021 to 2026, to reach USD 2.35 billion by 2026. The report delivers an in-depth understanding of the Airway Management Devices, historical and forecasted epidemiology as well as key companies involved in pipelines such as Smiths Medical PLC, Narang Medical Limited, Intersurgical Ltd, Teleflex Incorporated, Stryker Corporation, Medtronic PLC, and others.

Asthma Diagnostic Devices Market

"DelveInsight's 'Asthma Diagnostic Devices Market Insight, Competitive Landscape and Market Forecast, 2026' report delivers an in-depth understanding of Asthma Diagnostic Devices and the historical and forecasted Asthma Diagnostic Devices market trends, drivers, barriers, and key companies involved such as Medline Industries, Becton, Dickinson and Company, Siemens Process Instrumentation, Smiths Medical, Vyaire Medical, Nihon Kohden Corporation, Vitalograph, Circassia Limited, Intermedical (UK) Limited, and several others.

Chronic Obstructive Pulmonary Disease Treatment Devices Market

"DelveInsight's 'Chronic Obstructive Pulmonary Disease Treatment Devices Market Insight, Competitive Landscape and Market Forecast, 2026' report delivers an in-depth understanding of Chronic Obstructive Pulmonary Disease Treatment Devices and the historical and forecasted Chronic Obstructive Pulmonary Disease Treatment Devices market trends, drivers, barriers and key companies involved such as GlaxoSmithKline plc, Novartis AG, Merck & Co., Koninklijke Philips N.V, AstraZeneca, 3M, GF HEALTH PRODUCTS, Sunovion Pharmaceuticals Inc, Smiths Medical, Baxter, and others.

Other Trending Reports

Chronic Myelocytic Leukemia CML Market
Congenital Hyperinsulinism Market
Diabetes Insipidus Market
Limbal Stem Cells Deficiency Market
Syncope Market
Proteus Syndrome Market
Intestinal Obstruction Market
Allergic Asthma Due to Dermatophagoides Farinae Market
Bag3-related Gene Therapies Market
Tay-Sachs Market

Interested to know more about the breakthrough happenings? Take a look at the posts below

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect With Us at LinkedIn | Facebook | Twitter

Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/respiratory-inhalers-market-is-expected-to-escalate-at-a-cagr-of-5-38-and-reach-usd-47-83-billion-by-2026--analyzes-delveinsight-301505176.html

SOURCE DelveInsight Business Research, LLP